

## Nosocomial and Community Acquired Urinary Tract Infections at a Teaching Hospital in North Central Nigeria: Findings from a Study of 12,458 Urine Samples

G.T.A. Jombo MBBS, MSc, FMCPATH, D.Z. Egah MBBS, MSc, FMCPATH, E.B. Banwat MBBS, MSc, FMCPATH, J.A. Ayeni AFIMLT, FIMLT, MSc

Department of Medical Microbiology, Jos university Teaching Hospital, Jos, Nigeria

### ABSTRACT

**Background:** Urinary tract infection (UTI) is still a problem not infrequently encountered in the course of clinical practice. This study was designed to ascertain its prevalence among both the in and out-patients and the antibiotic susceptibility pattern of the isolates.

**Method:** A retrospective analysis of data from all the urine samples processed at Jos university teaching hospital microbiology laboratory was undertaken for a period of 36 months (January 2000-December 2002). Samples had been collected, stored and processed by standard laboratory procedures. Results obtained were analysed using SPSS 11 statistical software and *P* values <0.05 were considered significant.

**Results:** Of the 12,458 urine samples studied comprising 43% males and 57% females: the overall prevalence of UTI was found to be 22%; 7.4% among males and a higher figure of 14.6% among females, this was statistically significant ( $p < 0.05$ ). The rate of nosocomial UTI was significantly higher than the community acquired type: 12.3% and 9.3% respectively ( $p < 0.05$ ). The commonest nosocomial isolate was *Klebsiella* spp while *Escherichia coli* were for community acquired group. *Staphylococcus aureus*, Coagulase negative *Staphylococcus*, *Proteus* spp and *Pseudomonas aeruginosa* were also common isolates. The most effective antibiotics were Ofloxacin, Ciprofloxacin and Cefuroxime.

**Conclusion:** In-patients especially should be encouraged to drink adequate water daily and practice "double urination" to reduce incidence of UTI. Ofloxacin, Ciprofloxacin and Cefuroxime should be considered first in the treatment of UTI in the absence of a susceptibility test.

**KEYWORDS:** Nosocomial; Community; Acquired urinary tract infection; Nigerian Hospital

Paper accepted for publication 19th May 2006.

### INTRODUCTION

Urinary tract infection (UTI) is infection involving part or all of the urinary tract<sup>1</sup>. It can be upper UTI (pyelonephritis, ureteritis) or lower UTI (cystitis, urethritis) with symptoms such as chills and rigours

where it is symptomatic<sup>2</sup>. The infection usually enters the system by an ascending route via the urethra in over 98% of cases<sup>3,4</sup>.

Patients with upper UTI present with symptoms such as fever (usually >38°C), chills and rigours, vomiting and pains in the loins<sup>5,6</sup>. On the other hand patients with lower UTI present with features such as frequency, urgency, dysuria, haematuria and suprapubic pain<sup>3,5</sup>. The exact data on the incidence of UTI in Nigeria is inconclusive. In other parts of the world studies showed that UTI was responsible for over one million hospital admissions in one year<sup>7,8</sup>. Studies have shown that about 1% of school girls aged 5-14 years have bacteriuria and this figure increases to 4% by young adulthood<sup>9</sup>. Also it has been found that 25-30% of women between the ages of 20-40 years have had UTIs and 10% of men over 65 years of age have bacteria in the urine<sup>10</sup>. Bacteria are by far the commonest causes of UTI compared to other agents such as Fungi (*Candida*, *Blastomyces*, *Coccidioidomyces*); parasites (*Trichomonas*, *Schistosoma*, *Plasmodium*, Threadworm) and viruses (Herpes simplex virus 2)<sup>11-14</sup>.

The rate of progression of any UTI depends on a number of variables, these among others include: the status of infected urinary tract; the immune status of the patient; virulence of the organism and the effectiveness or not of treatment that has been initiated<sup>15-17</sup>.

Several risk factors have been linked with the onset and progression of UTI. This consists of general factors such as: extremes of age; diabetes; impaired immunity (malnutrition, HIV/AIDS, cancer, chemotherapy)<sup>18-20</sup>. The local factors include: stones, benign prostatic enlargement, spinal cord injury, vesico ureteric reflux and foreign bodies in the urinary tract<sup>21-23</sup>.

The unrestricted use of antibiotics in our environment has led to the treatment of UTI being more difficult due to the emergence of resistant bacteria<sup>24-25</sup>. This difficulty is being noticed in the management of bacterial infections in other parts of the body as well. There is therefore the need for a periodic update of the knowledge of the health professional (who is continuously involved in the management of those patients) about the common and emerging bacterial agents of UTI with their antibiotic susceptibility patterns.

This will put them in a better position of decision making in the course of managing these patients<sup>26-30</sup>.

## MATERIALS AND METHODS

**Study Area:** The study was carried out at Jos University Teaching hospital (JUTH), situated in Jos city, the capital of Plateau state. The state is located in the north central Nigeria and has abundant hills and rock formations as well as a suitable temperate climate. The teaching hospital serves predominantly, the needs of all the states located in the north central part of the country such as: Taraba, Niger, Benue, Nassarawa, Kogi, and FCT Abuja.

**Study Design:** The study was retrospectively undertaken. Data generated by the microbiology laboratory of JUTH was compiled for a period of 36 consecutive months (Jan 2000-Dec 2002). These urine samples constituted primarily of patients from the general out patient department (GOPD) of JUTH, accidents and emergency unit, those on admission in the hospital wards and few referred samples from other health centres. These samples were grouped into two categories- community acquired (CAU) and nosocomial (NCU) based on the clinical data on request forms accompanying the samples.

Community acquired UTI (CAU) - this consists of urine samples from patients attended to on out patient basis, those on admission for less than 24 hours without initial diagnosis of UTI and those with UTI at the time of admission.

Nosocomial UTI (NCU) - this consists of urine samples from patients on admission for more than 24 hours of which UTI was not diagnosed at the time of admission.

Urine samples were collected in sterile universal bottles (about 15 millimetres) and processed immediately or stored in the laboratory refrigerator at 4°C until the appropriate time<sup>31,32</sup>. Concentration procedure using centrifugation at 1500rpm was carried on every sample and sediment examined under X40 objective of the microscope for pus cells, red blood cells, casts, crystals, parasites and bacteria. The uncontaminated urine samples were inoculated into CLED (cysteine lactose electrolyte deficient), Mac-Conkey agar and Chocolate agar<sup>33,34</sup>. Sabouraud dextrose agar medium was included whenever there was suspicion of fungal involvement. The culture plates were incubated at 36.5°C over night in atmospheric air. Biochemical tests were carried out based on the gram reactions of the bacterial agents while antibiotic susceptibility tests on the isolates was done based on modified Kirby-Bauer's method which is a diffusion method<sup>35</sup>. All the laboratory

procedures were carried out by senior laboratory technologists experienced in bacteriological analysis while internal quality control measures were put in place.

## ANALYSIS OF RESULTS

The results were analysed using statistical software SPSS 11.0 and P values < 0.05 were considered significant.

## ETHICAL CONSIDERATION

Ethical approval for the study was sought for and obtained from the ethical committee of JUTH.

## RESULTS

From January 2000 to December 2002, a total of 12,458 urine samples were collected and processed at the microbiology laboratory of Jos university teaching hospital (JUTH).

Table I shows the age and sex distribution pattern of the subjects from whom the urine samples were collected. The highest age range from whom samples were collected was 30-39 years (2,648; 21.2%), followed by 20-29 years range (2,305; 18.5%), and thirdly, 40-49 years old (2,018; 16.2%); and the least age range was 70 years and above (697; 5.6%). There were 5,357 (43%) males and 7,101 (57%) females. The overall rate of infection was found to be 22% (n=2741): 7.4% (n=919) among males and 14.6% (n=1,822) among females. This higher figure among females was found to be statistically significant, p=0.0000000; OR=1.82 and RR=1.61.

Table II shows the rate of urinary tract infection among the nosocomial group as compared to the community acquired group. The rate of nosocomial UTI was found to be higher (12.3%; n=1,535) than the community acquired group of 9.3% (n=1,158) and unclassified group 0.4% (n=48). This was found to be statistically significant, p=0.0000000; OR= 0.85; RR= 0.91.

Table III shows the organisms isolated from the 12,458 urine samples studied. The commonest nosocomial isolate was *Klebsiella spp* (435; 28%), while that of community acquired was *Escherichia coli* (379; 32.4%). Other organisms that were also prevalent in the study include: *Staphylococcus aureus* (NCU=182, 11.7%; CAU= 132, 11.3%); Coagulase negative *Staphylococci* (NCU=154, 9.9%; CAU=106, 9.1%); *Proteus spp* (NCU= 168, 10.8%; CAU= 74, 6.3%); *Pseudomonas aeruginosa* (NCU= 72, 4.6%; CAU= 55, 4.7%); *Streptococcus faecalis* (NCU=63, 4.1%; CAU=22, 1.9%). Other organisms encountered with lesser frequency were: *Trichomonas vaginalis* (NCU=52,

3.3%; CAU= 19, 1.6%); *Streptococcus pyogenes* (NCU=21, 1.4%; CAU=42, 3.6%); *Enterobacter spp* (NCU= 26, 1.7%; CAU=22, 1.9%), and *Citrobacter spp* (NCU=19, 1.2%; CAU=18, 1.5%). Multiple infections were found to be commoner among the nosocomial isolates of UTI however, the difference was found to be statistically insignificant ( $p>0.05$ ).

Table IV and V shows antibiotic susceptibility patterns of the bacterial isolates from the urine samples under study. All the nosocomial isolates of *Streptococcus faecalis* were found to be resistant to Penicillin, Tetracycline, Ampicillin and Cloxacillin. The sensitivity pattern of other antibiotics against *S. faecalis* was similarly low (less than 50%) except for Ofloxacin, Ciprofloxacin and Cefuroxime which had sensitivities of 66%, 57% and 68% respectively. A higher sensitivity pattern of 86%, 67% and 86% respectively for the same drugs was recorded with the community acquired isolates of the same organism. This difference was found to be statistically significant ( $p<0.05$ ). *Pseudomonas aeruginosa* was also found to be highly resistant to the majority of the antibiotics tested among both the nosocomial and community acquired isolates. Less than 50% of the isolates of *P. aeruginosa* were sensitive to Ampicillin, Co-trimoxazole, Gentamicin, Augmentin, and Chloramphenicol among the nosocomial isolates while triple 88% sensitivity was recorded respectively among the community acquired isolates with Ofloxacin, Ciprofloxacin and Cefuroxime. This difference was also found to be statistically significant ( $p<0.05$ ). All the community acquired isolates of *P. aeruginosa*, similar to their nosocomial counterpart, were resistant to Ampicillin, Nitrofurantoin, Penicillin, Nalidixic acid, Tetracycline and Cloxacillin ( $p>0.05$ ).

Over 50% of the nosocomial isolates of *Escherichia coli* were sensitive to Gentamicin, Nitrofurantoin, Augmentin, Chloramphenicol and Cefuroxime, while a sensitivity of over 80% was recorded with Ceftriaxone and Ofloxacin. Less than 50% of the same organisms were found to be sensitive to Ampicillin, Penicillin, Tetracycline, Co-trimoxazole, Nalidixic acid and Cloxacillin. Higher sensitivity patterns were recorded with community acquired isolates with Ofloxacin, Ciprofloxacin and Cefuroxime showing 100% sensitivity. This difference was found to be statistically significant, ( $p<0.05$ ).

All the community acquired isolates of *Klebsiella spp* were sensitive to Ofloxacin, Cefuroxime and Ciprofloxacin: this was with a corresponding sensitivity of 87%, 65% and 65% respectively among the nosocomial isolates of the same organism. This

difference was similarly found to be statistically significant, ( $p<0.05$ ).

The nosocomial isolates of *Staphylococcus aureus* were highly resistant (over 50%) to many antibiotics such as the Penicillins, Tetracycline and Chloramphenicol while the highest sensitivity of 68% was recorded with Ofloxacin. Higher sensitivities were however recorded with the community acquired isolates: 82%, 83%, 87% and 83% respectively for Ofloxacin, Augmentin, Ciprofloxacin and Cefuroxime. These differences were also found to be statistically significant, ( $p<0.05$ ). A similar pattern of sensitivity was recorded among both the community acquired and nosocomial isolates of coagulase negative *Staphylococcus* except for Augmentin which showed significantly lower sensitivity among the nosocomial isolates.

There were no dramatic differences in the sensitivity patterns of the nosocomial and community acquired isolates of *Streptococcus pyogenes* in the study. However, the Penicillins and Tetracycline recorded higher sensitivities among the community acquired isolates of the organism as compared to the nosocomial counterpart but with no significant difference ( $p>0.05$ ).

Less than 50% of the nosocomial isolates of *Proteus spp* were sensitive to the Penicillins, Tetracycline, Co-trimoxazole, Nitrofurantoin, Augmentin, Nalidixic acid and Chloramphenicol. The sensitivity pattern among the community acquired isolates was comparatively higher as 65%, 73%, 92%, 78%, 78% and 90% sensitivity was recorded with Gentamicin, Ceftriaxone, Ofloxacin, Augmentin, Ciprofloxacin, and Cefuroxime respectively.

Both *Enterobacter spp* and *Citrobacter spp* from the nosocomial and community acquired isolates showed similar sensitivity patterns with the majority of the antibiotics. A low sensitivity of 19% was recorded with Tetracycline, Nitrofurantoin, Nalidixic acid and Chloramphenicol against the nosocomial isolates of *Enterobacter spp*: while 21% sensitivity was the lowest recorded with *Citrobacter spp* against Penicillin, Tetracycline and Chloramphenicol. Community acquired isolates of these organisms showed comparatively higher sensitivity patterns but with no significant difference ( $p>0.05$ ): a sensitivity of 100% was recorded with Ceftriaxone, Ofloxacin and Cefuroxime against *Citrobacter spp* while 100%, 98%, 96%, and 98% was respectively recorded for Ofloxacin, Ceftriaxone, Augmentin and Cefuroxime against *Enterobacter spp*.

**Table I. Age and Sex Distribution of Urinary Tract Infection (UTI) among the Urine Samples Studied in North Central Nigeria**

Age Years	M		F		TOTAL
	No Isolate	Isolate	No Isolate	Isolate	
<1-9	321(2.6)	52(0.4)	374(3.0)	71(0.6)	818(6.6)
10-19	507(4.1)	87(0.7)	586(4.7)	96(0.8)	1276(10.3)
20-29	750(6.0)	153(1.2)	883(7.1)	519(4.2)	2305(18.5)
30-39	838(6.7)	198(1.6)	1126(9.0)	486(3.9)	2648(21.2)
40-49	741(6.0)	164(1.3)	802(6.4)	311(2.5)	2018(16.2)
50-59	442(3.5)	89(0.7)	633(5.1)	92(0.7)	1256(10.0)
60-69	377(3.0)	54(0.5)	444(3.6)	83(0.6)	958(7.7)
70 & Above	289(2.3)	87(0.7)	225(1.8)	96(0.8)	697(5.6)
Unclassified	173(1.4)	35(0.3)	206(1.7)	68(0.5)	482(3.9)
TOTAL	4438(35.6)	919(7.4)	5279(42.4)	1822(14.6)	12458(100)

X<sup>2</sup> = 128.65; df = 1; p = 0.0000000; OR = 1.82; RR = 1.61  
 Parenthesis = percent

**Table II. The Rate of Nosocomial Urinary Tract Infection as Compared to Community Acquired Urinary Tract Infection in North Central Nigeria**

Infection (Type)	M		F		TOTAL
	No Infection	Infection	No Infection	Infection	
NCU	1767(14.2)	563(4.5)	1432(11.5)	972(7.8)	4734(38.0)
CAU	2568(20.6)	327(2.6)	3675(29.5)	831(6.7)	7401(59.4)
UCU	103(0.8)	29(0.3)	172(1.4)	19(0.1)	323(2.6)
TOTAL	4438(35.6)	919(7.4)	5279(42.4)	1822(14.6)	12,458(100)

X<sup>2</sup> = 60.12; df = 1; p = 0.0000000; OR = 0.85; RR = 0.91

**Key**

Parenthesis = percent  
 NCU – Nosocomial UTI  
 CAU – Community acquired UTI  
 UCU – Unclassified UTI

**Table III. Organisms Isolated from Nosocomial and Community Acquired Urinary Tract Infection in North Central Nigeria**

Organisms	NCU (%)	CAU (%)
<i>Klebsiella species</i>	435(28.0)	268(23.0)
<i>Escherichia coli</i>	332(21.4)	379(32.4)
<i>Staphylococcus aureus</i>	182(11.7)	132(11.3)
Coag. Negative <i>Staphylococcus</i>	154(9.9)	106(9.1)
<i>Proteus species</i>	168(10.8)	74(6.3)
<i>Streptococcus pyogenes</i>	21(1.4)	42(3.6)
<i>Streptococcus faecalis</i>	63(4.1)	22(1.9)
<i>Pseudomonas aeruginosa</i>	72(4.6)	55(4.7)
<i>Enterobacter species</i>	26(1.7)	22(1.9)
<i>Citrobacter species</i>	19(1.2)	18(1.5)
Yeast cells	17(1.1)	25(2.1)
<i>Trichomonas vaginalis</i>	52(3.3)	19(1.6)
Others	12(0.8)	7(0.6)
TOTAL	*1553(100)	**1169(100)

**Key**

Parenthesis = percent  
 NCU – Nosocomial UTI  
 CAU – Community acquired UTI  
 \* - 18 urine samples had multiple infections  
 \*\* - 11 urine samples had multiple infections

**Table IV. Antibiotic Susceptibility Pattern of the Bacterial Isolates from the Urine of Nosocomial Urinary Tract Infection (NCU) in North Central Nigeria.**

ISOLATES	Percentage susceptibility patterns*																		
	N	AMP	P	A	N	T	I	B	I	O	T	C	S	CLX	LIN	CIPRO	CHL	CFUR	OB
<i>Escherichia coli</i>	332	43	21	36	-	-	47	56	89	58	85	89	36	43	-	77	51	83	-
<i>Klebsiella species</i>	435	56	24	28	-	-	49	61	93	54	87	77	48	39	-	85	49	85	-
<i>S. aureus</i>	182	27	5	3	-	-	35	47	67	-	88	56	-	18	-	85	28	58	-
Coag. Neg. Staph.	154	19	7	9	-	-	38	44	75	-	76	42	-	20	-	58	31	56	-
<i>S. pyogenes</i>	21	32	26	26	-	-	61	66	71	-	89	71	-	23	-	74	44	71	-
<i>S. faecalis</i>	63	0	0	0	-	-	5	18	47	-	66	37	-	0	-	57	18	68	-
<i>P. aeruginosa</i>	72	0	0	0	-	-	23	22	56	0	64	46	0	0	-	84	18	66	100
<i>Proteus species</i>	168	34	17	13	-	-	42	53	73	38	71	48	34	16	-	73	27	54	0
<i>Enterobacter species</i>	26	30	25	19	-	-	50	69	73	19	73	50	19	23	-	76	19	50	0
<i>Citrobacter species</i>	19	37	21	21	-	-	63	58	68	37	68	37	37	32	-	72	21	58	0

**Key**  
 \* = Calculated to the nearest whole numbers; N = Number of Isolates recovered; 0 = All resistant; - = Not tested  
 NIT Nitrofurantoin  
 AMP Ampicillin  
 CLX Cloxacillin  
 TET Tetracycline  
 CEZ Cefazidime  
 COT Co-trimoxazole  
 CFTR Ceftriaxone  
 OFLOX Ofloxacin  
 AUG Augmentin  
 NAL Nalidixic acid  
 CHL Chloramphenicol  
 P Penicillin  
 RIF Rifampicin  
 CFUR Cefuroxime  
 CIPRO Ciprofloxacin  
 GEN Gentamicin  
 LIN Lincomycin

**Table V. Antibiotic Susceptibility Pattern of the Bacterial Isolates from the Urine Samples of Community acquired Urinary Tract Infection (CAU) in North Central Nigeria.**

ISOLATES	Percentage Susceptibility Patterns*																		
	N	AMP	P	A	N	T	I	B	I	O	T	C	S	CLX	LIN	CIPRO	CHL	CFUR	OB
<i>Escherichia coli</i>	379	58	43	55	-	-	67	83	96	88	100	89	78	67	-	100	87	100	-
<i>Klebsiella species</i>	268	63	45	58	-	-	75	89	98	94	100	86	74	63	-	100	93	100	-
<i>S. aureus</i>	132	48	33	43	-	-	42	65	76	-	82	83	-	53	-	87	56	83	-
Coag. Neg. Staph.	106	44	41	57	-	-	39	69	74	-	84	86	-	56	-	84	53	74	-
<i>S. pyogenes</i>	42	48	49	63	-	-	54	88	98	-	100	95	-	62	-	95	68	98	-
<i>S. faecalis</i>	22	5	0	5	-	-	10	47	55	-	86	67	-	0	-	67	10	86	-
<i>P. aeruginosa</i>	55	0	0	0	-	-	18	52	67	0	88	66	0	0	-	88	18	88	100
<i>Proteus species</i>	74	26	16	32	-	-	52	65	73	16	92	78	16	16	-	78	52	90	0
<i>Enterobacter species</i>	22	40	18	18	-	-	50	55	98	98	100	96	68	68	-	94	92	98	0
<i>Citrobacter species</i>	18	38	33	17	-	-	54	61	100	89	100	94	83	61	-	96	88	100	-

**Key**  
 \* = Calculated to the nearest whole numbers; N = Number of Isolates recovered; 0 = All resistant; - = Not tested  
 NIT Nitrofurantoin  
 AMP Ampicillin  
 CLX Cloxacillin  
 TET Tetracycline  
 CEZ Cefazidime  
 COT Co-trimoxazole  
 CFTR Ceftriaxone  
 OFLOX Ofloxacin  
 AUG Augmentin  
 NAL Nalidixic acid  
 CHL Chloramphenicol  
 P Penicillin  
 RIF Rifampicin  
 CFUR Cefuroxime  
 CIPRO Ciprofloxacin  
 GEN Gentamicin  
 LIN Lincomycin

**DISCUSSION**

The study was carried out to ascertain the prevalence of urinary tract infection vis-à-vis the nosocomial and community acquired patterns and the antibiotic susceptibility of the respective isolates. A major limitation for the study was how to group the urine samples into nosocomial urinary tract infection (NCU) and community acquired urinary tract infection (CAU) based on the clinical data accompanying the samples. This data is subject to errors based on wrong diagnosis and incomprehensive information by the requesting physician which is a common phenomenon in our hospitals. This difficulty was however resolved by arbitrarily grouping all the urine samples from the hospital wards (without prior detection of urinary tract infection on admission) as nosocomial; although, it has been well established that nosocomial infections can be contracted from the out patient clinic, while community acquired infections could manifest 24 hours after admission in the hospital<sup>36</sup>.

The overall prevalence of urinary tract infection (UTI) in the study was found to be 22%; 7.4% among males and 14.6% among females. This finding is lower than that of a previous study among AIDS patients in the same centre<sup>37</sup> where a prevalence of 24% was obtained. The higher figure in the previous study is expected since it was carried out among AIDS patients with obvious immunosuppression. The lower figure of 10.6% UTI<sup>37</sup> among non AIDS patients reported in the same centre earlier could also explain the higher figure in the present study: since the AIDS pandemic presently has taken a great toll on a large number of hospital visitations and admissions; this along with other immunosuppressive states such as: Diabetes mellitus, renal diseases, and

malnutrition could as well contribute to the higher figure in the present study<sup>38</sup>. Lower figures were reported by Onyemelukwe *et al*<sup>10</sup> and higher figures by Olowu *et al*<sup>11</sup>: the former due to the fact that the study was carried out on normal healthy pregnant women with no symptoms of UTI; while the later was on patients with pre-morbid renal pathological lesions.

The rate of nosocomial UTI (NCU) was found to be 12.3% as compared to that of community acquired UTI (CAU) which was lower (9.3%). The significantly higher rate of UTI ( $P < 0.05$ ) among the in-patients could be attributed to the UTI predisposing diseases including those earlier listed which might have been the cause of hospital admission in the first instance as well as some treatment procedures including drugs<sup>38,39</sup>.

The commonest bacterium causing nosocomial UTI was found to be *Klebsiella spp* (28%), followed by *Escherichia coli* (21.4%) and *Staphylococcus aureus* (11.7%). This may be as a result of the ability of *Klebsiella spp* to survive better in immunosuppressed tissues. Olowu *et al*<sup>11</sup> had a similar finding. On the other hand the commonest cause of community acquired UTI was found to be *Escherichia coli* (32.4%), followed by *Klebsiella spp* (23%) and *Staphylococcus aureus* (11.2%). This finding is similar to that of Brown *et al*<sup>12</sup> and Okoeguale<sup>9</sup> in their separate studies. *E. coli* is known for specific adaptations in the urinary tract that enhance its virulence<sup>40</sup>.

Urinary tract infection is therefore a common finding among both the out-patients and the in-patients. Investigations for pyrexia of unknown origin both in children and adults should consider the possibility of a UTI. Patients on admission in the hospital should be encouraged to drink at least 2 litres of water daily where clinical conditions warrant. This will encourage urination, reduce urinary stasis and subsequently wash the urinary passage ways of bacteria. Also patients as well as normal persons should be encouraged to empty bladder after urinating seems complete (double urination). Other practices such as urinating after sexual intercourse, avoiding nylon underwear and vaginal deodorants will also help reduce the incidence of UTIs drastically even among those at a higher risk of the disease.

Generally the antibiotic susceptibility patterns of the nosocomial isolates were lower than that of their community acquired counterpart. Both the community acquired and nosocomial isolates of *P. aeruginosa* were resistant to Ampicillin, Penicillin, Tetracycline, Nitrofurantoin, Nalidixic acid and Cloxacillin. The most sensitive antibiotics against the nosocomial isolates of

*P. aeruginosa* were Cefuroxime (66%), Ciprofloxacin (64%) and Ofloxacin (64%); while those most sensitive against their community acquired counterpart were the same drugs each with 88% sensitivity. This significant difference in sensitivity is expected since the nosocomial isolates have repeated exposure to these drugs leading to the development of resistance against them<sup>41</sup>.

This resistance by bacteria can be transferred from one drug to another in the same family after exposure to a single member in the family.

A similar high level of resistance was also recorded with *Streptococcus faecalis*: the most sensitive drugs among the nosocomial isolates were Ofloxacin (66%), Ciprofloxacin (57%) and Cefuroxime (68%), while a correspondingly higher sensitivity pattern was recorded from the community acquired isolates of *S. faecalis* as 86%, 67%, and 86% respectively and 55% for Gentamicin.

The sensitivity pattern of *Escherichia coli*, *Klebsiella spp*, *Staphylococcus aureus*, coagulase negative *Staphylococcus*, and *Proteus spp* from the nosocomial isolates was significantly lower than that of their community acquired counterparts for the majority of the drugs tested. Drugs such as Ampicillin, Penicillin, Tetracycline, Cloxacillin and Co-trimoxazole generally recorded low sensitivity among virtually all the isolates. The general abuse of these drugs by the public here comes to the open and the need to entrench proper legislation in the country on the sale, purchase and consumption of antibiotics becomes more necessary now than ever. This will help reduce the difficulty being encountered presently in the management of simple bacterial infections. This pattern of resistance has been found to be commoner and has been on the increase in the developing world for about two decades<sup>42,43</sup> now and abuse cannot be absolved from the blame. *Citrobacter spp* and *Enterobacter spp* however did not show significant differences in the sensitivities of the isolates of both the nosocomial and community acquired bacterial isolates against majority of the antibiotics in the study. This unexpected finding may be as a result of reduced rate of mutation of these bacteria as well as reduced cross transfer of resistant genes with other members of the Enterobacteriaceae. More work however, will be required in this direction to prove these hypotheses. The rate of development of penicillinase by *Streptococcus pyogenes* is generally slow<sup>30</sup>; this may account for the slow rate of induction of the nosocomial isolates of this bacterium towards the development of resistance as found in this study.

The drugs with the highest sensitivities on all the

isolates in the study but with a correspondingly significantly lower sensitivity for the nosocomial isolates were: Ofloxacin, Ciprofloxacin, Cefuroxime, Ceftriaxone and Augmentin. These drugs are less commonly abused; moreover their exorbitant cost to some extent controls their rate of abuse hence preserving their relatively higher efficacious states. This finding agrees with that of Dromigny *et al*<sup>43</sup> in Dakar, Senegal.

In conclusion, UTI is common among both the in-patients and out-patients but commoner among the former. Frequent ingestion of water, double urination and disuse of nylon pants could reduce its incidence among the two groups. A proper legislation on the sale and purchase of antibiotics in the country should be put in place to reduce the rate of antibiotics abuse. Finally, Ceftriaxone, Ofloxacin, Cefuroxime and Ciprofloxacin should be considered first in the treatment of UTI in the absence of a comprehensive sensitivity test.

## REFERENCES

1. Delzell JE, Lefevre ML. Urinary tract infections during pregnancy. *Am Family Physician* 2000; 61: 713 - 721.
2. Strom B L, Collins M, West S L, *et al*. Sexual activity, contraceptive use, and other risk factors for symptomatic and asymptomatic bacteriuria: a case control study. *Ann Intern Med* 1987; 107: 816 - 823.
3. Hooton T M, Scholes D, Hughes J P, *et al*. A prospective study of risk factors for symptomatic urinary tract infection in young women. *N Engl J Med* 1996; 335: 468 - 474.
4. Hagberg L I, Engberg R, Freter J, *et al*. Ascending unobstructed urinary tract infection in mice caused by pyelonephritogenic *Escherichia coli* of human origin. *Infect Immun* 1983; 40: 273 - 283.
5. Pryles C V, Eliot C R. Pyuria and bacteriuria in infants and children. The value of pyuria as a diagnostic criterion of urinary tract infections. *Am J Dis Child* 1965; 110: 628 - 635.
6. Stamm W E, Hooton T M. Management of urinary tract infections in adults. *N Engl J Med* 1993; 329(18): 1228 - 1334.
7. Foxman B, Barlow R, D'arey H, *et al*. Urinary tract infections: self reported incidence and associated costs. *Ann Epidemiol* 2000; 10: 509 - 515.
8. Okwara FN, Obimbo EM, Wafula EM, Marila FV. Bacteraemia, urinary tract infection and malaria in hospitalized febrile children in Nairobi: is there an association? *East Afri Med J* 2004; 81(1): 47 - 51.
9. Okoeguale M I. An assessment of current management of childhood urinary tract infections amongst private medical practitioners in Benin-city, Nigeria. *Nig Med Practitioner* 2004; 45(5): 72 - 75.
10. Onyemelukwe NF, Obi S N, Ozumba B C. Significant bacteriuria in pregnancy in Enugu, Nigeria. *Journal of College of Medicine* 2003; 8(2): 20 - 22.
11. Olowu W A, Oyetunji T G. Nosocomial significant bacteriuria: Prevalence and pattern of bacterial pathogens among children hospitalized for non-infective urinary tract disorders. *West Afri J Med* 2003; 22(1): 75 - 75.
12. Brown B J, Asinobi A O, Fatunde P K, Osinusi K, *et al*. Antimicrobial sensitivity patterns of organisms causing urinary tract infection in children with sickle cell anaemia in Ibadan, Nigeria. *West Afri J Med* 2003; 22(2): 43 - 48.
13. Banwat E B, Egah D Z, Gomwalk NE, *et al*. Asymptomatic bacteriuria in pregnant women attending the antenatal clinic of Plateau specialist hospital, Jos, central Nigeria. *Journal of Medicine in the Tropics* 2002; 4(2): 35 - 40.
14. Ibadin MO. Childhood urinary tract infection in Benin-city: pathogens and antimicrobial sensitivity pattern. *Journal of Medicine and Biomedical Research* 2002; 1(2): 22 - 28.
15. Kesah C N, Egri-Okwaji MTC, Odugbemi T O, Iroha E O. Bacteria associated with nosocomial infections and their antimicrobial resistance pattern in paediatric patients in a tertiary health institution. *J Med & Med Sciences* 1999; 1(1): 6 - 13.
16. Aghaji AE, Ugwumba F O. Bacterial cystitis in females: A review. *Journal of college of Medicine* 2004; 9(1): 63 - 68.
17. Buschelman B J, Bale M J, Jones R N. Species identification and determination of high level aminoglycoside resistance among enterococci, comparison study of sterile body fluid isolates 1985-1991. *Diag Microbiol Infect Dis* 1993; 16(2): 119 - 122.
18. Mobley H L, Chippendale G R, Swihart K G, Welch R A. Cytotoxicity of the HpmA haemolysin and urease of *Proteus mirabilis* and *Proteus vulgaris* against cultured human renal proximal tubular epithelial cells. *Infect Immun* 1991; 81: 719 - 730.
19. Mobley H L, Warren J N. Urease positive bacteria and obstruction of long term urinary catheters. *J Clin Microbiol* 1987; 25: 2216 - 2217.
20. Esposito A L, Gleckman R A, Cram S, *et al*. Community acquired bacteriuria in the elderly: analysis of one hundred consecutive episodes. *J Am Geriatr* 1980; 28: 315 - 319.
21. Jones R N, Kugler K C, Pfaller M C, *et al*. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY antimicrobial surveillance program, 1997. *Diagn Microbiol Infect Dis* 1999; 33: 55 - 63.
22. Muratani T, Matsumoto T. Bacterial resistance to antimicrobials in urinary isolates. *Int J Antimicrob Agents* 2004; 24(suppl 1): S28 - 31.
23. Biggi A, Dardanelli I, Pomero G *et al*. Acute cortical scintigraphy in children with first urinary tract infection. *Paediatr Nephrol* 2001; 16: 733 - 738.

24. Ishikawa K, Miyakawa S, Tanaka T, *et al.* The trend and susceptibility to antibacterial agents of *Enterococcus* species from urinary tract infections. *Nippon Hinyokika Gakkai Zasshi* 2004; 95(1): 25-34.
25. Zhanel GG, Laing N M, Nichol K A, *et al.* Antibiotic activity against urinary tract infection ( UTI) isolates of Vancomycin-resistant *Enterococci* (VRE): results from the 2002 North American Vancomycin resistant *Enterococci* susceptibility study (VAVRESS). *J Antimicrob Chemoter* 2003; 52(3): 382 - 388.
26. Mobley H L, Belas V, Lockett G *et al.* Construction of a flagellum negative mutant of *Proteus mirabilis*: effect on internalization by human renal epithelial cells and virulence in a mouse model of ascending urinary tract infection. *Infect Immunol* 1996; 64: 5332 - 5340.
27. Mei J M, Nourbakhsh F, Ford C W, Holden DW. Identification of *Staphylococcus aureus* virulence genes in a murine model of bacteraemia using signature tagged mutagenesis. *Mol Microbiol* 1997; 26: 399 - 407.
28. Pitout N, Thompson K S, Hanson N D. B-lactamases responsible for resistance to expanded-spectrum cephalosporins in *Klebsiella pneumonia*, *Escherichia coli* and *Proteus mirabilis* isolates recovered in South Africa. *Antimicrob Agents Chemoter* 1998; 42: 1350 - 1354.
29. Johnson D E, Lockett C V, Hall-Craigs M, *et al.* Uropathogenicity in rats and mice of *Providencia stuartii* from long-term catheterized patients. *J Urol* 1987; 138: 632 - 635.
30. Kumamoto Y, Tsukamoto T, Matsukawa M, *et al.* Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2002). I. Susceptibility distribution. *Jpn J Antibiot* 2004; 57(3): 246 - 274.
31. Baron E J O, Peterson L R, Finegold S M. Bailey and Scott's Diagnostic Microbiology. 9<sup>th</sup> Edn. U S A Philadelphia: Mosby Publishing company 1990; 249 - 257.
32. Bachellor C D, Bernstein J M. Urinary tract infections. *Med Clin NAm* 1997; 81: 719 - 730.
33. Schechler W E. Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: a consensus panel report. Society of Healthcare Epidemiology of America. *Infect Control Hosp Epidemiol* 1998; 19: 114 -124.
34. Sahn D F. Surveillance of antimicrobial resistance patterns and data for urinary tract pathogens in the U S A. *Clin Drug Invest* 2001; 21(Suppl 1):1 - 5.
35. Stamm W E, Hooton T M. Diagnosis and treatment of uncomplicated urinary tract infection. *Infect Dis Clin North Am* 1997; 11: 551 - 581.
36. Mayon-White R T. An international survey of the prevalence of hospital-acquired infection. *J Hosp Infect* 1988; 11(supplA): 43 - 48.
37. Jombo G T A, Egah D Z, Banwat E B. Bacteriology of urinary tract infection among patients with acquired immunodeficiency syndrome in Jos, Nigeria. *Niger J Med* 2005; 14(4): 422 - 424.
38. Foxman B. Recurring urinary tract infection: incidence and risk factors. *Am J Public Health* 1990; 80: 331 - 333.
39. Remis R S, Gurwith M J, Gurwith D, *et al.* Risk patterns for urinary tract infection. *Am J Epidemiol* 1987; 126: 685 - 694.
40. Mobley H L, Island M D, Massad G. Virulence determinants of uropathogenic *Escherichia coli* and *Proteus mirabilis*. *Kidney Int Suppl* 1994; 47: S129 - 136.
41. Muratani T, Matsumoto T. Bacterial resistance to antimicrobials in urinary isolates. *Int J Antimicrob Agents* 2004; 29(suppl 1): S28 - 31.
42. Murray B E, Alvarado T, Kim K H, *et al.* Increasing resistance to Trimethoprim-Sulphamethoxazole among the isolates of *Escherichia coli* in developing countries. *J Infect Dis* 1985; 152: 1107 - 1113.
43. Dromigny J A, Ndoye B, Macondo E A, *et al.* Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Dakar, Senegal: a multicentre study. *Diagn Microbiol Infect Dis* 2003; 47(4): 595 - 600.